Testing BI 3034701 Injections for Weight Loss in Adults With Obesity or Overweight

What this Trial Is About

Researchers are evaluating whether a medicine called BI 3034701 can help adults living with obesity or overweight lose weight. The study includes adults aged 18 to 74 years who have a body mass index BMI of 30 or more, or a BMI of 27 or more with at least one weight-related health problem. People with type 2 diabetes are not allowed to participate. The study is a phase II treatment trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of seven groups, with six groups receiving different doses of BI 3034701 and one group receiving a placebo that looks like the medicine but contains no active drug. Each participant receives two injections under the skin every week for 42 weeks. Alongside the injections, all participants receive counseling to help improve their diet and encourage regular exercise. The study lasts about 10 months for each participant. During the study, participants visit the study site 15 times where their body weight is regularly measured and laboratory tests are performed. They also complete questionnaires about their well-being and keep diaries of their food intake and physical activity. Researchers monitor health status and any side effects throughout the trial. The main measure of success is the percentage change in body weight after 42 weeks of treatment, with additional measures including weight loss milestones, waist size, and blood pressure changes.

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight